Experimental drug offered to patients with rare neurological disease
NCT ID NCT07380165
Summary
This program provides access to an investigational drug called levacetylleucine for people with Ataxia-Telangiectasia (A-T), a rare and serious neurological disease. It's designed for patients who cannot participate in regular clinical trials and have no satisfactory alternative treatments available. Doctors can request this medication for eligible patients when they believe the potential benefits outweigh the risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATAXIA-TELANGIECTASIA (A-T) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.